Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Trend Edge rates AKTS Bullish with a Setup Score of 0, net conviction 17, actionability 0. How the Setup Score works →
| Total Setup Score | 0 |
|---|---|
| Directional Bias | Bullish |
| Net Conviction | 17 |
| Actionability | 0 (no mans land) |
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer,… Read full Trend Edge analysis →
| Current Price | $16.64 |
|---|---|
| Market Cap | $987M |
| Float | 28.6M |
| Shares Outstanding | 53.7M |
| Price/Sales (TTM) | 98.08 |
| vs. Analyst Target | +112.7% to analyst PT |
| Operating Margin (TTM) | -853.99% |
| Revenue (TTM) | $10.1M |
| Dividend Rate | None |
| Analyst Target Price | $35.39 (10 analysts) |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2020 | $1.8M | -$40.9M | -$624,000 | -$29.0M |
| 2021 | $15.3M | -$59.2M | -$4.1M | -$52.8M |
| 2022 | N/A | -$17.9M | N/A | -$17.5M |
| 2023 | $27.1M | -$28.6M | -$3.1M | -$27.4M |
| 2024 | $1.5M | -$44.0M | $1.5M | -$42.4M |
| 2025 | $6.5M | -$63.7M | $6.5M | -$61.4M |
| Quarter | Revenue | Net Income |
|---|---|---|
| Mar 2025 | $1.4M | -$15.0M |
| Dec 2025 | $1.9M | -$15.1M |
| Mar 2026 | $3.2M | -$18.3M |
| Jun 2026 | $3.4M | -$24.1M |
| Insider Ownership | 14.1% |
|---|---|
| Institutional Ownership | 73.0% |
| Short Float | 11.1% |
| % of All Funds Holding | 1.31% |
| Number of Funds Holding | 115 |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $21.98 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $21.28 | Medium-term trend |
| Weekly | 80-Week SMA | $0.00 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $0.00 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $21.41 | Near-term monthly trend |
| Monthly | 20-Month SMA | $0.00 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $0.00 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Volume shelf data not available.
| Timeframe | Avg Return | Median | Win Rate | Best | Worst |
|---|---|---|---|---|---|
| Gap | 1.69% | 0.76% | 100.00% | 4.05% | 0.27% |
| 1 Day | 6.98% | 7.99% | 100.00% | 8.16% | 4.79% |
| 1 Week | 1.70% | 1.26% | 100.00% | 2.66% | 1.18% |
| 2 Weeks | 8.92% | 9.03% | 100.00% | 9.37% | 8.36% |
| 1 Month | 18.72% | 18.72% | 100.00% | 20.03% | 17.41% |
Next earnings: November 12, 2026 (29 days away)
Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).
Institutional holder breakdown coming soon.
Total institutional ownership: 73.0%
Total insider ownership: 14.1%
Founder-led management: Todd Foley (Co-Founder & Chairman)
| Total Filings | 11 |
|---|---|
| Net Value | -$2.5M |
| Net Shares Change | 40,555,006 |
| % of Float | 141.9% |
| C-Suite Filings | 3 |
| Clusters Detected | 2 |
| Name | Title | Net Value | Filings | Activity |
|---|---|---|---|---|
| EcoR1 Capital, LLC | +$40.0M | 1 | 1 buy | |
| MPM BIOVENTURES 2018, L.P. | +$20.0M | 1 | 1 buy | |
| GADICKE ANSBERT | +$20.0M | 1 | 1 buy | |
| Vida Ventures II, LLC | +$15.0M | 1 | 1 buy | |
| Kim Helen Susan | +$15.0M | 1 | 1 buy | |
| Foley Todd | +$4.2M | 1 | 1 buy | |
| Ron-Bigger Shulamit | Chief Operating Officer | -$1.2M | 1 | 1 sell |
| Czibere Akos | Chief Medical Officer | -$1.1M | 1 | 1 sell |
| Period | Filings | Insiders | Net Value | Seniority |
|---|---|---|---|---|
| 2026-01-12 – 2026-01-14 | 6 | 6 | +$114M | |
| 2026-07-10 – 2026-07-21 | 4 | 3 | -$2.5M | 2 C-suite |
| Date | Insider | Title | Net Value | Price After |
|---|---|---|---|---|
| 2026-07-21 | Herrmann Ken | -$116,414.83 | Transaction at $12.58, now +32.3% | |
| 2026-07-20 | Herrmann Ken | -$77,013.336 | Transaction at $12.64, now +31.6% | |
| 2026-01-14 | MPM BIOVENTURES 2018, L.P. | +$20.0M | Transaction at $18.00, now -7.6% | |
| 2026-01-14 | GADICKE ANSBERT | +$20.0M | Transaction at $18.00, now -7.6% | |
| 2026-01-12 | Vida Ventures II, LLC | +$15.0M | Transaction at $18.00, now -7.6% | |
| 2026-01-12 | Kim Helen Susan | +$15.0M | Transaction at $18.00, now -7.6% |
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Aktis Oncology, Inc. Common stock (AKTS) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for AKTS on Trend Edge →